Literature DB >> 9080887

Survey of in vivo sensitivity to chloroquine by Plasmodium falciparum and P. vivax in Lombok, Indonesia.

D J Fryauff1, J K Baird, D Candradikusuma, S Masbar, M A Sutamihardja, B Leksana, S Tuti, H Marwoto, T Richie, A Romzan.   

Abstract

A malariometric survey was conducted in 14 villages of Sekotong district, in Lombok, Indonesia during October 1994. Point prevalence of malaria ranged from 0% to 15% in the surveyed villages, averaging 6% overall, and Plasmodium falciparum accounted for 63% of the infections. Forty-nine patients with uncomplicated malaria and parasite counts ranging from 40 to 10,800 asexual forms/microliter were enrolled in a 28-day in vivo test of chloroquine sensitivity. All subjects received a supervised therapeutic regimen of chloroquine (25 mg base/kg over a 48-hr period) and parasitemia and symptoms were closely monitored for 28 days. Asexual parasites were eliminated within four days in the 29 P. falciparum and 20 P. vivax study patients enrolled. The cumulative incidence of therapeutic failure (recurrent symptomatic parasitemia) among P. falciparum cases at days 7, 14, and 28 was 7%, 10%, and 14% (4 of 29), respectively. However in all four cases, parasitemias recurred against chloroquine blood levels below the minimally effective concentration (MEC) of 200 ng/ml and do not confirm chloroquine resistance. All 20 P. vivax parasitemias were sensitive to chloroquine and the blood remained clear, with the exception of one case in which an asymptomatic parasitemia appeared on day 28. Parasitemias by P. falciparum and P. vivax that were observed before supervised therapy, but in the presence of whole blood chloroquine above normally suppressive MEC levels, suggest resistance to suppressive or prophylactic regimens of chloroquine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9080887     DOI: 10.4269/ajtmh.1997.56.241

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  8 in total

1.  Human malaria in immunocompromised mice: new in vivo model for chemotherapy studies.

Authors:  A Moreno; E Badell; N Van Rooijen; P Druilhe
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 2.  Chloroquine resistance in Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  In vitro anti-malarial drug susceptibility of temperate Plasmodium vivax from central China.

Authors:  Feng Lu; Qi Gao; Kesinee Chotivanich; Hui Xia; Jun Cao; Rachanee Udomsangpetch; Liwang Cui; Jetsumon Sattabongkot
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

4.  In vitro susceptibility of Plasmodium vivax to antimalarials in Colombia.

Authors:  Diana Fernández; César Segura; Margarita Arboleda; Giovanny Garavito; Silvia Blair; Adriana Pabón
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

Review 5.  Malaria distribution, prevalence, drug resistance and control in Indonesia.

Authors:  Iqbal R F Elyazar; Simon I Hay; J Kevin Baird
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

6.  Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.

Authors:  Inge Sutanto; Dedeh Endawati; Liem Hui Ling; Ferdinand Laihad; Rianto Setiabudy; J Kevin Baird
Journal:  Malar J       Date:  2010-02-12       Impact factor: 2.979

7.  The ability of chloroquine to prevent tat-induced cytokine secretion by monocytes is implicated in its in vivo anti-human immunodeficiency virus type 1 activity.

Authors:  Fabienne Rayne; Agnès Vendeville; Anne Bonhoure; Bruno Beaumelle
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

8.  High proportions of pfhrp2 gene deletion and performance of HRP2-based rapid diagnostic test in Plasmodium falciparum field isolates of Odisha.

Authors:  Pallabi Pati; Gunanidhi Dhangadamajhi; Madhusmita Bal; Manoranjan Ranjit
Journal:  Malar J       Date:  2018-10-29       Impact factor: 2.979

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.